This article is more than 5 years old. Information may no longer be current.

Injunction prohibits generic versions of cinacalcet through 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A US District Court granted an injunction preventing commercialized general versions of Amgen’s cinacalcet until the drug’s US patents expire in 8 years.

Cinacalcet, marketed by Amgen under the name Sensipar, is FDA approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

According to an Amgen press release, the court upheld three patents for cinacalcet. The injuction will prevent Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd. and Barr Laboratories, Inc. from commercializing generic versions.

Cinacalcet was first approved by the FDA in March 2004. The last patent extension protecting the drug will expire in March 2018, according to Amgen.

Follow EndocrineToday.com on Twitter.